94% of users think they encounter genAI online, but just 44% can spot it, fueling the need for labels and tougher brand transparency.
The tool lets brands spin 30-second tracks from text, photos, or videos, threatening stock libraries and startups.
43% of shoppers worldwide say difficulty assessing product quality is the main reason they avoid buying certain products on online marketplaces, making it the leading barrier to purchase, according to a January report from ChannelEngine and Sapio Research.
The Supreme Court has ruled that most of President Donald Trump’s tariff policies, which were imposed under the International Emergency Economic Powers Act (IEEPA), are unconstitutional.
However, getting shoppers to check out is more challenging as deal-hunting becomes the norm.
Experian, Insurify, and Tuio have launched apps that let consumers compare quotes and explore coverage through conversation.
Catastrophe losses are an expected cost of doing business—but climate change is making them harder to model.
Its roadmap signals a growing digital-only threat to high street banks.
AI search adds shoppable carousels to community threads, testing whether intent can turn into transactions.
Rising net charge-offs raise concerns about the Aussie platform’s consumer financial health.
Following Klarna and OnePay, the small BNPL provider looks to mobile phone plans to power its super app play.
Square’s deep bench of partners offers SMBs more integrated tools to push their businesses forward.
A 6-3 ruling voids IEEPA duties, relieving AI, retail, and cloud sectors squeezed by import costs.
Quicker, reliable AI notes help clinicians reclaim minutes they can spend on patients, even as AI accuracy concerns persist.
Tragic news moves consumers’ health choices, signaling to healthcare marketers that they need to pay attention to key cultural moments, not just paid celebrity endorsements.
Justices curb Trump’s tariffs, but a national security case could sustain pharma import taxes.
Single-study clinical trials (versus two) become the default, speeding up common drug approvals, while vaccines still face tougher scrutiny.
Get the correct answers to our Big Question quiz in the EMARKETER Daily newsletter.